Keywords: Tumors, Contrast Agent, Brain Tumor, RelativityNew gadolinium-based contrast agents (GBCAs) with high relaxivity could have an impact on decision making and treatment planning of brain metastases (BM). In this post-hoc analysis , patients with BM who underwent two separate magnetic resonance imaging (MRI) examinations, one with gadopiclenol and one with gadobenate dimeglumine, both at 0.1 mmol/kg, were included. This study showed that gadopiclenol at the dose of 0.1 mmol/kg improved detection and characterization of BM, and led to a change in treatment decisions in 2 of 13 patients.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords